APA (7th ed.) Citation

Silberstein, S., Diamond, M., Hindiyeh, N. A., Biondi, D. M., Cady, R., Hirman, J., . . . Smith, J. (2020). Eptinezumab for the prevention of chronic migraine: Efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study. Journal of headache and pain, 21(1), 120-12. https://doi.org/10.1186/s10194-020-01186-3

Chicago Style (17th ed.) Citation

Silberstein, Stephen, et al. "Eptinezumab for the Prevention of Chronic Migraine: Efficacy and Safety Through 24 weeks of Treatment in the Phase 3 PROMISE-2 (Prevention of Migraine via Intravenous ALD403 Safety and Efficacy–2) Study." Journal of Headache and Pain 21, no. 1 (2020): 120-12. https://doi.org/10.1186/s10194-020-01186-3.

MLA (9th ed.) Citation

Silberstein, Stephen, et al. "Eptinezumab for the Prevention of Chronic Migraine: Efficacy and Safety Through 24 weeks of Treatment in the Phase 3 PROMISE-2 (Prevention of Migraine via Intravenous ALD403 Safety and Efficacy–2) Study." Journal of Headache and Pain, vol. 21, no. 1, 2020, pp. 120-12, https://doi.org/10.1186/s10194-020-01186-3.